What drove today’s RO.SW stock drop?

Intraday selling followed Roche’s earnings-window commentary and investor reassessment of pipeline timing, particularly the CT-388 Phase II news. The RO.SW stock fell to **CHF346.40** as traders balanced development optimism against premium valuation and upcoming guidance.

How does Roche’s valuation compare to peers for RO.SW stock?

Roche trades at a high price-to-book near **9.47** and a quoted PE of **29.48**, above many drug manufacturers. That premium reflects diagnostics strength and cash flow, but it increases sensitivity to pipeline setbacks for RO.SW stock.

What is Meyka AI’s forecast for RO.SW stock?

Meyka AI's forecast model projects **CHF384.78** (monthly) for RO.SW stock, an implied **11.08%** upside versus **CHF346.40**. Forecasts are model-based projections and not guarantees; use them with other analysis.

Should income investors consider RO.SW stock for dividends?

Roche pays **CHF9.70** per share with a yield near **2.87%** and a payout ratio around **0.68**, which suits income investors seeking stability. Dividend exposure must be balanced with valuation and pipeline risk for RO.SW stock.

CH Stocks

RO.SW down 3.62% intraday 29 Jan 2026: Roche Holding AG (SIX) earnings focus CT-388

ByHuzaifa Zahoor January 29, 2026

The market opened sharply on Roche Holding AG after the group reported results tied to its earnings release on 29 Jan 2026 and intraday selling pushed the RO.SW stock to CHF346.40, down 3.62% from yesterday. Volume is light at 25,080 shares but price action reflects investor focus on pipeline news, notably the Phase II obesity drug CT-388. Today’s move ties valuation questions to near-term catalysts and dividends as traders reprice risk on the SIX in Switzerland.